ArticleNeuroImage. Clinical2017
Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication.
Article in NeuroImage. Clinical, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Diffusion tensor imaging in Parkinson's disease: Review and meta-analysis.NeuroImage. Clinical · 2017Pooled it
- Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.Movement disorders : official journal of the Movement Disorder Society · 2025Review
- Investigating white matter alterations in Parkinson's disease using multi-shell free-water DTI and NODDI: insights into neurodegeneration and levodopa effects.Frontiers in neurology · 2025Article
- Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?Current neuropharmacology · 2024Review
- Neuroimaging and plasma evidence of early white matter loss in Parkinson's disease with poor outcomes.Brain communications · 2024Article
- Neuroinflammation and Mitochondrial Dysfunction in Parkinson's Disease: Connecting Neuroimaging with Pathophysiology.Antioxidants (Basel, Switzerland) · 2023Review
- Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Thalamic white matter macrostructure and subnuclei volumes in Parkinson's disease depression.NPJ Parkinson's disease · 2022Article
- Comparison of Olfactory Tract Diffusion Measures Between Early Stage Parkinson's Disease Patients and Healthy Controls Using Ultra-High Field MRI.Journal of Parkinson's disease · 2022Article
- Diffusion Magnetic Resonance Imaging-Based Biomarkers for Neurodegenerative Diseases.International journal of molecular sciences · 2021Review
- Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Differences in network controllability and regional gene expression underlie hallucinations in Parkinson's disease.Brain : a journal of neurology · 2020Article
- Advanced diffusion magnetic resonance imaging in patients with Alzheimer's and Parkinson's diseases.Neural regeneration research · 2020Review
- Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction.Neurology · 2020Article
- MRI biomarkers of motor and non-motor symptoms in Parkinson's disease.Parkinsonism & related disorders · 2020Review
- Dementia risk in Parkinson's disease is associated with interhemispheric connectivity loss and determined by regional gene expression.NeuroImage. Clinical · 2020Article
- Article
- Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.Current neurology and neuroscience reports · 2018Review
- Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease.AJNR. American journal of neuroradiology · 2018Article
- Validation of diffusion tensor imaging measures of nigrostriatal neurons in macaques.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveA prior longitudinal study demonstrates that free-water diffusion magnetic resonance imaging (dMRI) tracks progression in the substantia nigra (Ofori et al., 2015b). Here, we test the acute effects of antiparkinsonian medication on this established imaging progression marker for the first time.
methodsFifteen PD patients underwent dMRI OFF and ON-medication one day apart. ON-medication, patients were tested approximately 45 min after their usual dose of antiparkinsonian medication. OFF-medication, patients were tested after not taking antiparkinsonian medication for > 12 h. OFF and ON-medication was counter-balanced across subjects. For dMRI, we computed free-water and free-water corrected fractional anisotropy (FA
resultsON-medication significantly reduced parkinsonian motor symptoms compared with OFF-medication (
conclusionsAdministration of an acute does of anti-parkinsonian medication in PD does not affect free-water and FA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.